Roche. Q sales. Basel, 19 April 2016

(1)

(2)

Roche

Q1 2016 sales

(3)

3 This presentation contains certain forward-looking statements. These forward-looking

statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’,

‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among

other things, strategy, goals, plans or intentions. Various factors may cause actual results to

differ materially in the future from those reflected in forward-looking statements contained in

this presentation, among others:

1 pricing and product initiatives of competitors;

2 legislative and regulatory developments and economic conditions;

3 delay or inability in obtaining regulatory approvals or bringing products to market;

4 fluctuations in currency exchange rates and general financial market conditions;

5 uncertainties in the discovery, development or marketing of new products or new uses of existing

products, including without limitation negative results of clinical trials or research projects, unexpected

side-effects of pipeline or marketed products;

6 increased government pricing pressures;

7 interruptions in production;

8 loss of or inability to obtain adequate protection for intellectual property rights;

9 litigation;

10 loss of key executives or other employees; and

11 adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to

mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily

match or exceed the historical published earnings or earnings per share of Roche.

For marketed products discussed in this presentation, please see full prescribing information on our website

www.roche.com

(4)

4 Group

Severin Schwan

(5)

Q1 2016: Good start to the year

5 Growth

Sales

Innovation

Diagnostics

Oncology

Neuroscience

1

_{At constant exchange rates (CER); NEDA=no evidence of disease activity; MRI=magnetic resonance imaging;}

IND: Investigational New Drug Application

• Group sales +4%

1 _{driven by HER2 franchise (+9%), Immunology franchise}

(+16%), Avastin (+4%), and Professional Diagnostics (+7%)

• Good growth

1 _{in all regions: US (+3%), Europe (+3%), Japan (+3%) and}

International (+7%)

• Atezolizumab: Acceptance of filing for advanced bladder and lung cancer in

the US

• Successful US launches of Alecensa and Cotellic

• US approval of Gazyva in R/R NHL (GADOLIN)

• US approval of Venclexta (venetoclax) in R/R CLL 17p deletion

• Ocrevus (ocrelizumab):

– Updated NEDA and MRI data at AAN (

April, 15

th

_{– 21}

st

₎

(6)

Q1 2016: Solid sales growth continues

6 CER=Constant Exchange Rates

2016

2015

CHFbn

CHF

CER

Pharmaceuticals Division

9.8

9.3

5

4 Diagnostics Division

2.6

2.5

4

5 Roche Group

12.4

11.8

5

4 Change in %

(7)

Q1 2016: Sales growth for fifth consecutive year

7 2%

6%

4%

6% 6%

4%

8%

7%

5%

4%

5%

6%

5%

7%

6%

4%

0%

2%

4%

6%

8%

10%

Q1

12 Q2

12 Q3

12 Q4

12 Q1

13 Q2

13 Q3

13 Q4

13 Q1

14 Q2

14 Q3

14 Q4

14 Q1

15 Q2

15 Q3

15 Q4

15 Q1

16

(8)

Q1 2016: Solid sales growth in all regions

8

0

1

2

3

4

5

6 Japan

International

Europe

US

Diagnostics

Pharma

CHFbn

+3%

+5%

+4%

-1%

+16%

-3%

0%

+3%

+7%

(9)

Roche significantly advancing patient care

Recognition for innovation 2013-present

9 Rank

Company

#

1 Roche

12

2 BMS

8

3 Novartis

7

3 Merck

6

3 Pfizer

6

4 GSK

5

12

Breakthrough Therapy

Designations

Year

Molecule

2016

Ocrelizumab

(PPMS)

Venclexta

(AML)

Venclexta

+

Rituxan

(R/R CLL)

2015

Actemra

(Systemic sclerosis)

Atezolizumab

(NSCLC)

Venclexta

(R/R CLL 17p del)

Emicizumab

/ACE 910 (Hemophilia A)

2014

Esbriet

(IPF)

Lucentis

(DR)

Atezolizumab

(Bladder)

2013

Alectinib

(2L ALK+ NSCLC)

Gazyva

(1L CLL)

Source:

http://www.focr.org/breakthrough-therapies

as at 22 March 2016; PPMS=Primary Progressive Multiple Sclerosis; CLL=Chronic

Lymphocytic Leukemia; NSCLC=Non-Small Cell Lung Cancer; IPF=Idiopathic Pulmonary Hypertension; DR=Diabetic Retinopathy

(10)

Significant launch activities ahead

10 Outcome studies are event-driven: timelines may change. Standard approval timelines of 1 year assumed.

Oncology/

hematology

Neuroscience

Ophthalmology

Immunology

FDA Breakthrough

Therapy Designation

Cotellic + Zelboraf

BRAFmut melanoma

Venclexta

R/R CLL with 17p del

Ocrelizumab

RMS/ PPMS

Lebrikizumab

Severe Asthma

Emicizumab (ACE910)

Hemophilia A

Atezolizumab

2L+ lung and bladder cancer

Alecensa

2L ALK+ NSCLC

Perjeta + Herceptin

eBC HER2+ (APHINITY)

Atezolizumab+Avastin+chemo

1L NSCLC

Gazyva

1L aNHL (GOYA)

Gazyva

1L iNHL (GALLIUM)

Gazyva

Refractory iNHL (GADOLIN

)

Lampalizumab

Geographic atrophy

Atezolizumab + Avastin

1L RCC

2016

2017

2018

Actemra

Giant cell arteritis

Alecensa

1L ALK+ NSCLC

Pharma

(11)

2016 outlook

11 Group sales growth

1 _{Low to mid-single digit}

Core EPS growth

1 _{Ahead of sales growth}

Dividend outlook

Further increase dividend in Swiss francs

(12)

12 Pharmaceuticals Division

Daniel O’Day

(13)

Q1 2016 sales

Innovation

Outlook

(14)

Q1 2016: Pharma sales

Good growth driven by all regions

14 CER=Constant Exchange Rates

2016

2015

CHFm

CHF

CER

Pharmaceuticals Division

9,800

9,322

5

4 United States

4,716

4,392

7

3 Europe

2,319

2,178

6

5 Japan

853

763

12

4 International

1,912

1,989

-4

4 Change in %

(15)

Q1 2016: Oncology and immunology driving

growth

15

15 Absolute values and growth rates at Constant Exchange Rates (CER)

-120

-60

0

60

120 Pegasys

Lucentis

Tarceva

Tamiflu

Activase/TNKase

Actemra/RoActemra

MabThera/Rituxan

Xolair

Avastin

Herceptin

Esbriet

Perjeta

US

Europe

Japan

International

+33%

+96%

+4%

+22%

+14%

+3%

-50%

-13%

+21%

CHFm

-14%

-6%

(16)

0

1

2

3 Alecensa

Zelboraf +

Cotellic

Xeloda

Tarceva

CD20

Avastin

HER2

Kadcyla

Perjeta

Herceptin

_+9%

+4%

-14%

-17%

+18%

MabThera/Rituxan

(Oncology)

Gazyva/Gazyvaro

+3%

Cotellic

+161%

Q1 2016: Oncology launches off to a good start

16 CHFbn

CER=Constant Exchange Rates

Q1 2016 Oncology sales: CHF 6.1bn; CER growth +4%

YoY CER growth

• Increased competition

• EU: Avastin + Tarceva filed in 1L EGFR+ NSCLC

• Loss of exclusivity

• Growth driven mainly by cervical and ovarian

• Strong uptake of Perjeta and Kadcyla

• Growth of Herceptin due to longer treatment

• Back to growth post launch of Cotellic

• Gazyva approved in R/R iNHL (GADOLIN)

• US: launch off to a strong start

(17)

HER2 franchise: Growth mainly driven by Perjeta

17

0

500 1,000

1,500

2,000

2,500

Q1 13

Q1 14

Q1 15

Q1 16

Herceptin

Perjeta

Kadcyla

+15%

YoY CER growth

+23%

+17%

CER=Constant Exchange Rates

CHFm

+9%

HER2 franchise Q1 2016

• Herceptin (+4%): Longer treatment duration

in combo with Perjeta

• Perjeta (+33%): Strong demand in 1L mBC

and neoadjuvant in the US and EU

• Kadcyla (+11%): Growth driven by EU,

International and Japan

Outlook 2016

• Herceptin: Further SC conversion

• Perjeta: Further increasing penetration

• Kadcyla: New launch countries

(18)

Avastin: Strong underlying growth

18 CER=Constant Exchange Rates

0

400

800 1,200

1,600

2,000

Q1 13

Q1 14

Q1 15

Q1 16

CHFm

US

Europe

International

Japan

YoY CER growth

+11%

+9%

+4%

+6%

Avastin Q1 2016

• Growth impacted by Health Insurance

Plan impact in Japan

• International (+27%): Driven by Asia,

mainly China (lung cancer launch)

Outlook 2016

• Continued uptake in ovarian and

cervical

• EU: Avastin + Tarceva approval in

EGFR+ NSCLC expected in H2

(19)

Immunology: Continued strong growth, now

>CHF 7bn on an annualised basis

19

0

300

600

900 1,200

1,500

1,800

Q1

13 Q1

14 Q1

15 Q1

16 MabThera/Rituxan (RA)

Actemra IV

Actemra SC

Xolair

CellCept

Pulmozyme

Esbriet

Other

CHFm

CER=Constant Exchange Rates; GPA=granulomatosis with polyangiitis; MPA=microscopic polyangiitis

YoY CER growth

+11%

+20%

+16%

Immunology Q1 2016

Xolair

(+22%)

• Continued strong uptake in allergic

asthma, chronic idiopathic urticaria

Actemra

(+14%)

• SC formulation driving growth

• Increasing 1L monotherapy leadership

focusing on MTX intolerant patients

MabThera/Rituxan

(+11%)

• Continues to grow in rheumatoid

(20)

Esbriet: Expanding beyond severe patients

20 CHFm

10

27

88

178

0

50

100

150

200 Q1

13 Q1

14 Q1

15 Q1

16 US

Europe

International

US (+145%)

• Strong underlying growth with patient

starts and treatment rate on track

• Around 100,000 IPF patients in the US

with high unmet need

EU (+36%)

• Increasing differentiation due to

strengthened label including the pooled

1 Yr mortality data

Outlook 2016

• Increasing patient pool and new launch

countries

YoY CER growth

+96%

(21)

Q1 2016 sales

Innovation

Outlook

(22)

**Venclexta* in R/R CLL with 17p deletion**

First Bcl-2 inhibitor with significant upside potential

22

• Accelerated approval in the US following breakthrough therapy designation in R/R CLL 17p del

• Additional breakthrough therapy designations: Venclexta+Rituxan in R/R CLL and Venclexta in AML

• Several read-outs at ASCO in NHL, CLL, MM and AML

NHL=non-hodgkin`s lymphoma; CLL=chronic lymphoid leukemia; MM=multiple myeloma; AML=acute myeloid leukemia;

* Venclexta (venetoclax) in collaboration with AbbVie

Phase II (M13-982)

Response,

n (%)

Venclexta

(n = 106)

ORR

85 (80.2)

CR/CRi

8 (7.5)

(23)

Ocrelizumab: Additional efficacy data at AAN

Breakthrough therapy designation in PPMS

23

• NEDA, disability progression and MRI data to be presented at AAN (April, 15

th

_{– 21}

st

₎

• Breakthrough therapy designation granted in PPMS

• US/EU filings in RMS/PPMS on track for H1 2016

(24)

Emicizumab (ACE 910) development plan

Non-interventional study expanded to all patients

24 QW=weekly dosing; Q2W=dosing every 2 weeks; Q4W=dosing every 4 weeks; OLE=open label extension

• Inhibitor study: Enrollment progressing well

• Inhibitor non-interventional study fully recruited (>90 patients) and expanded to non-inhibitors

• Non-inhibitor, pediatric and Q4W dosing studies expected to start in 2016

2015

2016

2017

2018

Pediatrics Inhibitor Non-interventional Inhibitor (≥12 yrs) Weight based QW dosing

Q4W dosing study Non-inhibitor (≥12 yrs)

QW and Q2W dosing Japanese studies

Chugai OLE

Phase II

Phase III

(25)

Unlocking the full value of cancer immunotherapy

New deals signed in Q1

25 Chen and Mellman. Immunity 2013

NME=new molecular entity; CIT=cancer immunotherapy; FP=fusion protein; TCB=T-cell bispecific

T cell Trafficking

Cancer T cell recognition

anti-CEA/CD3 TCB

anti-CD20/CD3 TCB

KTE-C19

*

(Kite Pharma)

ImmTAC

*

(Immunocore)

T cell infiltration

anti-VEGF (Avastin)

anti-Ang2/VEGF (vanucizumab)

T cell killing

anti-PDL1 (atezolizumab)

anti-CSF-1R (emactuzumab)

IDOi (NewLink)

IDOi

*

(Incyte)

CPI-444

*

(Corvus)

anti-TIGIT

IDO1/TDOi

*

(Curadev)

Antigen presentation

**T-Vec oncolytic virus* (Amgen)**

INF

a

anti-CD40

CMB305 vaccine

*

(Immune Design)

EGFRi (Tarceva)

ALKi (Alecensa)

BRAFi (Zelboraf)

MEKi (Cotellic)

anti-CD20 (Gazyva)

anti-HER2 (Herceptin;

Kadcyla; Perjeta)

various chemotherapies

**lenalidomide* (Celgene)**

**rociletinib* (Clovis)**

**daratumumab* (Janssen)**

Antigen release



Priming & activation

anti-CEA-IL2v FP (cergutuzumab amunaleukin)

anti-FAP-IL2v FP

anti-OX40

anti-CD27

*

(Celldex)

entinostat

*

(Syndax)



Clinical development

Preclinical development

*

Partnered or external

Established therapies

(26)

Cancer immunotherapy read-outs in 2016

Priority review granted for bladder and lung cancer

26 Status as of April 19, 2016; Outcome studies are event-driven: timelines may change.

Phase III

Phase I

= Read-outs expected in 2016

atezo NSCLC (Dx+) (BIRCH) atezo 2/3L NSCLC (POPLAR) atezo+Avastin 1L Renal (IMmotion 150) atezo 1/2L Bladder (IMvigor 210)

Phase II

atezo+lenalidomide MM atezo+daratumumab+len R/R MM atezo+ipilimumab Solid tumors atezo+aCD40 Solid tumors atezo+IFN-alfa Solid tumors atezo+aOX40 Solid tumors atezo+IDO Solid tumors atezo+Avastin+/-chemo Solid tumors atezo+Cotellic Solid tumors atezo+chemo Solid tumors atezo Solid tumors aOX40 Solid tumors aCEA/CD3 TCB Solid tumors aCEA-IL2v FP Solid tumors aCD20/CD3 TCB heme tumors atezo+/-azacitidine MDS atezo+Gazyva+chemo R/R FL/aNHL atezo+Gazyva+polatuzumab R/R FL/aNHL aFAP-IL2v FP Solid tumors IDO Solid tumors atezo+aCEA/CD3 TCB Solid tumors atezo+aCSF-1R Solid tumors atezo+aCEA-IL2v FP Solid tumors

atezo+Zelboraf

Melanoma

atezo+Tarceva NSCLC atezo+Gazyva R/R FL / aNHL atezo+Zelboraf+Cotellic Melanoma aCSF-1R Solid tumors atezo+Alecensa ALK+ NSCLC atezo+Kadcyla/Herceptin+Perjeta HER2+ eBC/mBC atezo+Gazyva+lenalidomide R/R FL/aNHL aCD40+vanucizumab R/R FL/aNHL atezo 2/3L NSCLC (OAK) atezo 2/3L Bladder (IMvigor 211) atezo+Avastin+chemo 1L nsq NSCLC (IMpower 150) atezo+chemo 1L nsq NSCLC (IMpower 130) atezo+chemo 1L sq NSCLC (IMpower 131) atezo 1L nsq NSCLC (Dx+) (IMpower 110) atezo 1L sq NSCLC (Dx+) (IMpower 111) atezo+chemo 1L TNBC (IMpassion 130) atezo

Adj MIBC (Dx+) (IMvigor 010)

atezo Adj NSCLC (Dx+) (IMpower 010) atezo+Avastin 1L Renal (IMmotion 151) atezo+chemo 1L nsq NSCLC (IMpower 132)

For Background:

New Ph3 in 3L CRC for

Tecentriq+Cotellic, FPI in

May’16, data in ‘18 (OS),

approval in Q1’19

(27)

Q1 2016 sales

Innovation

Outlook

(28)

2016: Focus on ongoing and upcoming launches

28 Approvals &

launch

preparation

Maximise

recent

launches

• Ocrevus

(ocrelizumab) in MS

• Atezolizumab

in bladder and lung cancer

• Gazyva

(GOYA) and Perjeta (APHINITY)

• Venclexta

(venetoclax) in R/R CLL with 17p deletion

• Cotellic + Zelboraf

in 1L BRAF positive metastatic melanoma

• Gazyva

in Rituxan-refractory iNHL (GADOLIN)

• Alecensa

in ALK positive NSCLC

(29)

2016 onwards: Significant launch activities

29 Outcome studies are event-driven: timelines may change. Standard approval timelines of 1 year assumed.

FDA Breakthrough

Therapy Designation

Oncology/

hematology

Neuroscience

Ophthalmology

Immunology

Cotellic + Zelboraf

BRAFmut melanoma

Venclexta

R/R CLL with 17p del

Ocrelizumab

RMS/ PPMS

Lebrikizumab

Severe Asthma

Emicizumab (ACE910)

Hemophilia A

Atezolizumab

2L+ lung and bladder cancer

Alecensa

2L ALK+ NSCLC

Perjeta + Herceptin

eBC HER2+ (APHINITY)

Atezolizumab+Avastin+chemo

1L NSCLC

Gazyva

1L aNHL (GOYA)

Gazyva

1L iNHL (GALLIUM)

Gazyva

Refractory iNHL (GADOLIN

)

Lampalizumab

Geographic atrophy

Atezolizumab + Avastin

1L RCC

NMEs

lin

e

ext

ensions

2016

2017

2018

Actemra

Giant cell arteritis

Alecensa

(30)

ASCO 2016: Highlights in various cancer types

30 Solid tumors

• atezolizumab + aOX40:

Ph I

• atezolizumab + Cotellic:

Ph I in CRC

Lung

• Alecensa:

Ph III (

J-ALEX

) in 1L ALK+ NSCLC

• atezolizumab:

Ph II OS update (

POPLAR)

in

2/3L NSCLC

Bladder

• atezolizumab:

Ph II (

IMvigor210

) 1L cohort and

2L cohort update in bladder

Breast

• Herceptin + Perjeta:

Ph III (

PHEREXA

) in 2L

HER2+ mBC

• atezolizumab + abraxane:

Ph I update in TNBC

Hematology

• Venclexta:

Ph II (

CAVALLI

) in 1L aNHL

• Venclexta:

Ph I in R/R CLL and R/R NHL

• Venclexta +/- chemo:

Ph I in R/R MM

• Venclexta + chemo:

Ph I in AML

(31)

Additional key oncology presentations in 2016*

31 * Planned submissions (to be confirmed); Outcome studies are event driven, timelines may change

• atezolizumab + abraxane:

Ph I in TNBC

• atezolizumab + IDOi:

Ph I

• atezolizumab + Zelboraf + Cotellic:

Ph1 in 1L BRAF+ mM

• atezolizumab:

Ph II (

IMvigor 210

) in bladder

• atezolizumab:

Ph I in SCLC

• atezolizumab:

Ph III (

OAK

) in 2L NSCLC

[or IASLC Vienna]

Copenhagen, 7-11 Oct

San Diego, 3-6 Dec

• atezolizumab + lenalidomide:

Ph I in MM (safety)

• atezoliztumab + azacytidine:

Ph I in MDS (safety)

• aCD20/CD3 TCB:

Ph I dose escalation in solid tumors

• Gazyva:

Ph III (

GOYA

) in front-line aNHL

• polatuzumab + Gazyva/Rituxan:

Ph II (

ROMULUS

) in R/R FL / aNHL

• polatuzumab + Gazyva/Rituxan + CHP:

Ph I/II in 1L aNHL

• polatuzumab + Gazyva:

Ph I/II in 1L aNHL and R/R FL

• Venclexta + Rituxan +/- bedamustin:

Ph II (

CONTRALTO

) in R/R FL

• Venclexta + Gazyva or +Rituxan +/- benda:

Ph I in R/R CLL

• Venclexta:

Ph II in ibrutinib/idelalisib ref R/R CLL

Vienna, 4-7 Dec

San Antonio, 6-10 Dec

• atezolizumab:

Ph III (

OAK

) in 2L NSCLC

• atezoliztumab + Tarceva:

Ph I in NSCLC

• atezolizumab + abraxane:

Ph I update in TNBC

• taselisib:

Ph II (

LORELEI

) in neoadjuvant HER2-/ER+ BC

• SERD:

Ph II

New Orleans, 16-20 Apr

Copenhagen, 9-12 Jun

• aOX40:

Ph I dose escalation in solid tumors

• atezoliztumab + Avastin + FOLFOX:

Ph I in CRC

• atezolizumab + Gazyva:

Ph I in R/R aNHL/iNHL

• idasanutlin + AraC

: Ph I in R/R AML

EHA

We are hoping to show

_{MM and MDS data at}

ASH but we cannot

confirm until later this

year.

(32)

2016: Key late-stage news flow

32 Compound

Indication

Milestone

Regulatory

Gazyva

Rituxan-refractory iNHL

US/EU approval

Venclexta

R/R CLL with 17p deletion

US approval

ocrelizumab

RMS/PPMS

US/EU filing

atezolizumab

Bladder cancer

US approval

atezolizumab

2/3L NSCLC

US approval

Alecensa

2L ALK+ NSCLC

EU CHMP opinion

Phase III readouts*

lebrikizumab

Severe asthma

Ph III LAVOLTA I/II

atezolizumab

2/3L NSCLC

Ph III OAK

Gazyva

Front-line aNHL

Ph III GOYA

Perjeta + Herceptin

Adjuvant HER2+ BC

Ph III APHINITY

Actemra

Giant cell arthritis

Ph III GiACTA

Alecensa

1L ALK+ NSCLC

Ph III ALEX

Phase II readouts*

lebrikizumab

Atopic dermatitis

Ph II TREBLE, ARBAN

atezolizumab

Bladder cancer

Ph II IMvigor 210 (1L cohort)

atezolizumab + Avastin

1L Renal cancer

Ph II IMmotion 150

Venclexta + Rituxan

R/R FL (iNHL)

Ph II CONTRALTO

Venclexta + Rituxan/Gazyva

1L aNHL

Ph II CAVALLI

* Outcome studies are event driven, timelines may change



mixed

(33)

33 Diagnostics Division

Roland Diggelmann

(34)

Q1 2016: Diagnostics Division sales

Strong sales growth in laboratory businesses

34 CER=Constant Exchange Rates; Underlying growth of Molecular Diagnostics excluding Sequencing business: +4%

2016

2015

CHFm

CHF

CER

Diagnostics Division

2,614

2,511

4

5 Professional Diagnostics

1,519

1,425

7

7 Molecular Diagnostics

446

401

11

11 Diabetes Care

443

507 -13

-11

Tissue Diagnostics

206

178

16

13 Change in %

(35)

North America

0%

27% of divisional sales

Latin America

+21%

6% of divisional sales

Japan

-3%

4% of divisional sales

EMEA

1 +1%

43% of divisional sales

Q1 2016: Diagnostics regional sales

Growth driven by Asia Pacific and Latin America

Asia Pacific

+16%

20% of divisional sales

35 23% growth in E7 countries

2

1

_{Europe, Middle East and Africa;}

2

_{Brazil, China, India, Mexico, Russia, South Korea, Turkey}

(36)

Q1 2016: Diagnostics highlights

Growth driven by Professional Diagnostics

36

• Driven by immunodiagnostics (+12%)

• Virology (+16%) incl. HPV (+16%)

• Advanced staining portfolio (+10%); primary

staining (+24%)

0.0

0.5

1.0

1.5

2.0 Tissue

Dia

Diabetes

Care

Molecular

Dia

Professional

Dia

EMEA

North America

RoW

+13%

-11%

+7%

+11%

CHFbn

1

_{Underlying growth of Molecular Diagnostics excluding sequencing business: +4%}

CER=Constant Exchange Rates; EMEA=Europe, Middle East and Africa

YoY CER growth

• Spillover of US reimbursement cuts to private

sector

(37)

Providing the full solution in hepatitis testing

Comprehensive menu in serology & molecular

37

1

_{Q1 2016 growth; *NAT: nucleic acid amplification technology}

Complete platform and test portfolio

• Hepatitis contributes ~60% of Roche’s

Infectious Disease/Virology portfolio

• Serology hepatitis: (+5%

1 ₎

• Molecular/NAT* hepatitis: (+11%

1 ₎

Roche

25%

Others

75%

Leader in a CHF 4.3bn market

• 5yr CAGR: ~6% projected

(38)

FDA approves IND for cobas Zika assay

Screening initiated at Puerto Rico blood centres

38 * IND: Investigational New Drug Application

• Currently testing in Puerto Rico, expect to

expand into southern US centres

• Operating under an IND* cost-recovery

model, no commercial sales

(39)

Key launches 2016

39 Area

Product

Market

Instruments /

Devices

Central

Laboratory

cobas 8000 <e 801>

– high throughput immunochemistry analyzer

cobas c 513

– high throughput dedicated HbA1c analyzer

EU

US

Point of Care

CoaguChek INRange (Zenith)

_{tooth connectivity}

– modified analyzer for intuitive self testing with full blue

EU

Sequencing

Roche SMRT Sequencer

_{with Pacific Biosciences)}

– single molecule sequencer for clinical research (in collaboration

WW

Diabetes

Care

Accu-Chek Guide

– next-generation blood glucose monitoring system

Accu-Chek Insight CGM

– new high-performance continuous glucose monitoring system

EU

Tests /

Assays

Virology

cobas 6800/8800 HIV Qual

– early Infant Diagnosis and Confirmatory HIV Test

EU

HPV /

Microbiology

cobas 6800/8800 CT/NG

– fully automated solution for screening and diagnosis of

Chlamydia

trachomatis

and

Neisseria gonorrhoeae in symptomatic & asymptomatic patients

EU

Point of Care

cobas Liat Influenza A/B plus RSV (CLIA)

assay for qualitative detection and discrimination of Influenza A virus, Influenza B virus and respiratory

– automated multiplex real time RT-PCR

syncytial virus (RSV)

US

Sequencing

ctDNA oncology panels

_selection

– liquid biopsy for circulating tumor DNA for cancer therapy

_US

Companion

Diagnostics

PD-L1 (SP142) for Bladder Cancer*

– companion diagnostic for atezolizumab

PD-L1 (SP142) for NSCLC*

– companion diagnostic for atezolizumab

US

(40)

40 Finance

Alan Hippe

(41)

Q1 2016: Highlights

41 Sales

• Good sales growth in all regions and both divisions

Capital markets update

• Bond maturity

– EUR: 2.1bn maturity on 4 March 2016 - coupon 5.625%

• Bond tender

– USD: 0.6bn (0.86bn outstanding, maturity in 2019) – coupon 6.0% s.a.

• Bond issuance

– EUR: 0.65bn maturity in 2023 - coupon 0.5%

– USD: 1.0bn maturity in 2026 - coupon 2.625% s.a.

Currency impact

• Positive impact from USD, JPY and EUR currencies partly offset by Latin America

s.a.=semi-annual coupon

Guidance for FY 2016

(42)

+457

+133

+124

+581

+107

+72

+30

+115

United States

Europe

Intl.

Japan

Diagnostics

Division

Group

Fx

Group

CHF

Pharma Division

+4%

+3%

+5%

+4%

+5%

+4%

+5%

1 Q1 2016: Group sales

Increase driven by US & EU Pharma and Diagnostics

42 Absolute values and growth rates at Constant Exchange Rates (CER)

(43)

CER

sales

growth

Q1 2016

vs.

Q1 2015

Exchange rate impact on sales growth

Positive impact from USD, JPY and EUR

CER=Constant Exchange Rates

+3.9%

+4.9%

+1.9p

+0.6p

+0.4p -0.2p

-0.2p

-0.2p -1.3p

CER

USD

JPY

EUR

Other

Europe

As-Pac

Other

Lat-Am

CHF

sales

growth

Q1 2016

vs.

Q1 2015

43

(44)

Currency impact on Swiss Franc results 2016

Low currency impact expected

Q1

HY

Sep

YTD

FY

Sales

1

0 Core

operating

profit

0 -1

Core EPS

-1

0 Assuming the 31 Mar 2016 exchange

rates remain stable until end of 2016,

2016 impact is expected to be (%p):

CHF / USD

CHF / EUR

+1%

+2%

1.01 0.99 0.98 0.97 0.97 0.97 0.97 0.97 0.97 0.97 0.97 0.97 0.97 0.98 0.99 0.97 0.95 0.95 0.95 0.96 J F M A M J J A S O N D 1.09 1.10 1.09 1.09 1.09 1.09 1.09 1.09 1.09 1.09 1.09 1.09 1.09 1.10 1.10 1.09 1.06 1.06 1.07 1.08 J F M A M J J A S O N D

Average

YTD

2015

4%

3%

2%

1%

2%

3%

2%

Assumed average YTD 2016

Monthly avg fx rates 2016 Fx rates at 31 March 2016

(45)

2015: Core EPS base for FY 2016 guidance

45 excl. Venezuela &

Argentina FX losses

13.49 +0.36

13.85 Full Year 2015

as reported

Core EPS

Full Year 2015

@ CER

(46)

2016 outlook

46 Group sales growth

1 _{Low to mid-single digit}

Core EPS growth

1 _{Ahead of sales growth}

Dividend outlook

Further increase dividend in Swiss francs

(47)

2016: Upcoming IR events

Further details available online:

http://www.roche.com/investors/agenda.htm

5 June

21 July

2 August

20 October

Analyst Event at ASCO

Half Year Results

Analyst Event on Diagnostics Division at AACC

Third Quarter Results

(48)

Pipeline summary

Marketed products additional indications

Global Development late-stage trials

pRED (Roche Pharma Research & Early Development)

gRED (Genentech Research & Early Development)

Roche Group Q1 2016 sales

Diagnostics

Foreign exchange rate information

(49)

Changes to the development pipeline

Q1 2016 update

49 New to Phase I

New to Phase II

New to Phase III

New to Registration

1 NME transitioned from Ph0

RG7906

– psychiatric disorders

1 NME re-opened in Ph1

RG7203

PDE10A inh – schizophrenia

1 NME in-licensed from Amgen

RG6149

ST2 MAb - asthma

1 NME acquired from Tensha

RG6146

BET inh – oncology (CIT)

3 new AIs

RG7876

CD40+vanucizumab solid tumors

RG7601

Venclexta+Cotellic/idasanutlin –

AML

RG3616

Erivedge+ruxolitinib –

myelofibrosis

1 NME in-licensed from

Shionogi

RG6152

CAP endonuclease inh -

influenza

1 NME transitioned from Ph2

RG7412

crenezumab –

Alzheimer’s

1 AI

RG7446

atezolizumab +

chemotherapy + pemetrexed –

NSCLC non-sq. 1L

1 AI transitioned from Ph2

RG7446

atezolizumab – NSCLC 2L+

Removed from Phase I

Removed from Phase II

Removed from Phase III

Removed from Registration

2 NMEs

RG7116

lumretuzumab – mBC

RG7597

duligotuzumab – solid tumors

1 NME

RG7090

basimglurant TRD

(out-licensing activities ongoing)

1 NME (status assigned to Ph1)

RG7155

emactuzumab PVNS

tumors

1NME following FDA approval

RG7601

Venclexta (venetoclax)

17pdel CLL rel/ref

(50)

Roche Group development pipeline

50 Phase I

(43 NMEs+19 AIs)

Raf & MEK dual inh solid tumors

ChK1 inh solid tum & lymphoma atezo+Zelboraf+/-Cotellic melanoma atezo+Avastin+chemo solid tumors

atezo+Tarceva /Alecensa NSCLC atezolizumab+Cotellic solid tumors

Venclexta (venetoclax)+Gazyva CLL atezolizumab solid tumors

ERK inh + Cotellic solid tumors LSD1 inh AML

Ly6E ADC solid tumors MDM2 (4) IV prodrug AML

ADC ovarian ca atezolizumab+ipi/IFN solid tumors

OX40 MAb solid tumors

ranibizumab PDS wAMD Nav1.7 inh pain

VEGF-ANG2 biMAb wAMD a-synuclein MAb Parkinson's Disease

RG3645 RG7893

RG7716 RG7935

HIF1 alpha LNA solid tumors

RG7304 RG7741 RG7446 RG7446 RG7446 RG7446 RG7601 RG7446 RG7842 RG6016 RG7841 RG7775 RG7882 RG7446 RG7888 RG6061

CEACD3 TCBRG7802 ± atezolizumab s. tumors

CD40 MAb+atezolizumab solid tumors RG7876 atezolizumab+Gazyva lymphoma RG7446

IL-22Fc inflammatory diseases RG7880 Cat-S antag autoimmune diseases RG7625

DBO β-lactamase inh bact. infections RG6080 emactuzumab + atezolizumab s. tumors RG7155

SERD (2) ER+(HER2-neg) mBC RG6047

IDO inh solid tumors RG6078

RG7601 Venclexta (venetoclax) heme indications

therapeutic vaccine HBV RG7944

*CEA IL2v FP+atezolizumab s. tumors RG7813

OX40 MAb + atezolizumab RG7888 solid tumors CLL

- fibrosis RG6069

RG7446 atezo+lenalidomide/daratumumab MM IDO inh + atezolizumab solid tumors RG6078

PTH1 recep. ago hypoparathyroidism CHU

polatuzumab vedotin heme tumors RG7596

V1 receptor antag autism RG7314 ipatasertib RG7440 solid tumors

Flu A MAb influenza A RG7745 nemolizumab (IL-31R) atopic dermatitis CHU

basmisanil Down’s syndrome RG1662 vanucizumab RG7221 mCRC Cotellic+paclitaxel TNBC RG7421 SERD ER+(HER2-neg) mBC RG6046

URAT1 inh gout CHU

RG3502 Kadcyla HER2+ NSCLC

RG3637 lebrikizumab +/- Esbriet IPF

olesoxime spinal muscular atrophy RG6083 TLR7 agonist HBV RG7795 RG3637 lebrikizumab atopic dermatitis

Phase II

(16 NMEs+12 Als)

CD20/CD3 biMAb heme tumors RG7828

ASO Huntington’s Disease IONIS Flu B MAb influenza B RG6024 FAP-DR5 biMAb solid tumors RG7386

RG3637 lebrikizumab COPD

- glaucoma

nemolizumab CHU (IL-31R) pruritus dialysis pts

danoprevir HCV RG7227 obinutuzumab renal transplant RG7159

Cadherin-11 MAb RA RG6125

RG4929

- HBV

FAP IL2v FP solid tumors

SMN2 splicer(2) spinal muscular atrophy BTK inh autoimmune diseases

StaphA vcRifalog TAC infect. diseases RG7834

RG7461

RG7916 RG7845

RG7861

FGFR1/KLB MAb metabolic diseases RG7992 RG7861

PT - hyperphosphatemia CHU

codrituzumab hepatocell. carcinoma RG7686 taselisib ER+(HER2-neg) BC neoadj RG7604 taselisib NSCLC sq 2L RG7604 Venclexta (venetoclax) DLBCL RG7601 Venclexta (venetoclax)+Rituxan FLrel/ref RG7601

obinutuzumab lupus nephritis RG7159

VAP-1 inh inflammatory diseases PRO

RG7159 Gazyva multiple combos heme indications

RG7446 atezolizumab + K/HP HER2+ BC

RG7888

Nav1.7 inh (2) pain RG6029 Erivedge+Esbriet IPF RG3616

ADC r/r NHL RG7986

RG-No Roche/Genentech managed CHU Chugai managed

IONIS IONIS managed PRO Proximagen managed Immunology

New Molecular Entity (NME) Oncology Other Ophthalmology Neuroscience Infectious Diseases CardioMetabolism Additional Indication (AI)

BET inh oncology RG6146

Erivedge+ruxolitinib myelofibrosis RG3616

PDE10A inh schizophrenia RG7203

- RG7906 psychiatric disorders

RG7601 Venclexta+Cotellic/idasanutlin AML CL

CAP endonuclease inh influenza RG6152

* INN: cergutuzumab amunaleukin

ST2 MAb asthma RG6149

SMN2 splicer spinal muscular atrophy RG7800

RG7876 CD40 MAb+vanucizumab solid tumors

(51)

Roche Group development pipeline

51 Phase III

(10 NMEs + 30 Als)

1 Global filing 2 CHMP positive opinion Q1’16 3 EU only 4 Approved in the US 5 Phase 3 ongoing

6 Approved in the US and Japan lampalizumab geographic atrophy RG7417

Avastin glioblastoma 1L RG435

ocrelizumab RMS RG1594 Gazyva DLBCL1L RG7159

ocrelizumab PPMS RG1594 Actemra large-vessel vasculitisCHU lebrikizumab severe asthma RG3637

Zelboraf melanoma adj RG7204

RG1273 Perjeta+Herceptin HER2+gastric ca 1L

Actemra giant cell arteritis RG1569

etrolizumab ulcerative colitis RG7413

RG1273 Perjeta+Herceptin HER2+ mBC 2L

Alecensa (alectinib) ALK+ NSCLC 1L RG7853

Gazyva iNHL rituximab-refractory RG71594

Gazyva follicular lymphoma 1L RG7159

RG7601 Venclexta (venetoclax)+RituxanCLL rel/ref

RG1450 gantenerumab Alzheimer’s

atezolizumab NSCLC 2L+

Kadcyla + Perjeta HER2+ BC adj RG3502

Kadcyla + Perjeta HER2+ BC neoadj RG3502 IL-6R MAb neuromyelitis optica CHU Perjeta+Herceptin RG1273 HER2+ BC adj

Kadcyla HER2+ BC adj RG3502

Venclexta RG7601 (venetoclax)+Gazyva CLL 1L RG4351 Avastin rel. ovarian ca. Pt-sensitive

RG74465 atezolizumab bladder cancer 2L

atezolizumab+Avastin RCC RG7446

MabThera SC RG1052 CLL Avastin+Tarceva EGFR mut+ NSCLC RG4353

RG7446 atezolizumab+chemo NSCLC non-sq. 1L 1L NSC RG7446 atezo+chemo+Avastin NSCLC non-sq. 1L

atezolizumab Dx+ NSCLC sq. 1L RG7446 atezolizumab Dx+ NSCLC non-sq. 1L RG7446

taselisib ER+(HER2-neg) mBC RG7604

etrolizumab Crohn’s disease RG7413 MabThera pemphigus vulgaris RG105

atezolizumab+abraxane TNBC RG7446 atezolizumab Dx+ NSCLC adj RG7446

atezolizumab RG7446 muscle inv. bladder ca adj

Registration

(2

NMEs + 4 Als)

Alecensa (alectinib) ALK+ NSCLC 2L RG78536

idasanutllin AML RG7388 emicizumab hemophilia A RG6013

Actemra systemic sclerosis RG1569

New Molecular Entity (NME)

RG-No Roche/Genentech managed CHU Chugai managed

IONIS IONIS Managed PRO Proximagen managed

RG105 MabThera is branded as Rituxan in US and Japan

RG1569 Actemra is branded as RoActemra in EU

RG7159 Gazyva is branded as Gazyvaro in EU Oncology

Neuroscience Infectious Diseases CardioMetabolism Additional Indication (AI) Immunology Other crenezumab Alzheimer’s Ophthalmology RG7412 RG74465 RG7446 atezo+chemo+pemetrexed NSCLC non-sq. 1L atezolizumab+chemo NSCLC sq. 1L RG7446

Status as of April 19, 2016

(52)

NME submissions and their additional indications

Projects currently in phase 2 and 3

52 Unless stated otherwise, submissions are planned to occur in US and EU

✓

indicates a submission which has occurred with regulatory action pending * EU submission pending

ocrelizumab (RG1594) RMS danoprevir (RG7227) HCV crenezumab (RG7412) Alzheimer‘s gantenerumab (RG1450) Alzheimer‘s V1 receptor antag (RG7314) autism codrituzumab (RG7686) liver cancer lampalizumab (RG7417) geographic atrophy lebrikizumab (RG3637) severe asthma etrolizumab (RG7413) ulcerative colitis

2016

2019 and beyond

atezolizumab (RG7446) US* NSCLC 2L+ ✓ ipatasertib (RG7440) solid tumors vanucizumab (RG7221) colorectal cancer lebrikizumab+/-Esbriet (RG3637) IPF

2017

atezolizumab(RG7446) combo Avastin RCC Flu A MAb (RG7745) influenza taselisib (RG7604)

HER2 neg ER+ mBC

basmisanil (RG1662) Down syndrome atezolizumab (RG7446) US* bladder cancer 2L ✓ Venclexta (venetoclax) DLBCL ocrelizumab (RG1594) PPMS emicizumab (RG6013) hemophilia A Venclexta (venetoclax) + Gazyva CLL 1L Venclexta (venetoclax) + Rituxan FL rel/ref taselisib ( RG7604) NSCLC sq 2L

2018

olesoxime (RG6083) SMA atezolizumab(RG7446)+ chemo NSCLC non-sq 1L etrolizumab (RG7413) Crohn’s disease atezolizumab(RG7446) NSCLC sq 1L (Dx+) atezolizumab(RG7446) NSCLC non-sq 1L (Dx+) atezolizumab(RG7446)+ chemo NSCLC sq 1L taselisib ( RG7604) ER+(HER2-neg) BC neoadj New Molecular Entity

Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other Venclexta (venetoclax) + Rituxan CLL rel/refractory lebrikizumab (RG3637) atopic dermatitis TLR7 ago (RG7795) HBV atezolizumab (RG7446) NSCLC adj (Dx+) atezolizumab (RG7446) + abraxane TNBC atezolizumab (RG7446) MIBC adj lebrikizumab (RG3637) COPD VEGF/ANG2 biMAb (RG7716) wAMD polatuzumab vedotin (RG7596) heme tumors SERD (RG6046) ER+(HER2-neg) mBC idasanutlin (RG7388) AML

CAP endonuclease inh (RG6152) influenza atezolizumab(RG7446)+chemo + Avastin NSCLC non-sq 1L atezolizumab(RG7446)+chemo +pemetrexed NSCLC non-sq 1L

Status as of April 19, 2016

(53)

2016

2019 and beyond

✓

indicates submission to health authorities has occurred

*approved in EU

Unless stated otherwise, submissions are planned to occur in US and EU.

Submissions of additional indications for

existing products

Projects currently in phase 2 and 3

53

Actemra systemic sclerosis Perjeta + Heceptin HER2-pos. BC adj. Perjeta+Herceptin HER2-pos. gastric cancer 1L

Kadcyla HER2-pos. BC adj. Actemra

giant cell arteritis

2017

Avastin (US) GBM Gazyva DLBCL 1L Neuroscience Ophthalmology Other NME Oncology Immunology Infectious Diseases CardioMetabolism Perjeta + Herceptin HER2-pos. mBC 2L *Avastin rel. ovarian ca. Pt-sens.

Kadcyla+Perjeta HER2-pos. BC adj. Kadcyla+Perjeta

HER2-pos. BC neoadj HER2-pos. NSCLC Kadcyla

2018

Zelboraf melanoma adj. MabThera pemphigus vulgaris ranibizumab PDS (US) wAMD Alecensa (alectinib) Alk+ NSCLC 1L obinutuzumab lupus nephritis Cotellic+paclitaxel TNBC Gazyva follicular lymphoma 1L

Status as of April 19, 2016

(54)

Major granted and pending approvals 2016

54

Neuroscience Ophthalmology Other NME Oncology Immunology Infectious Diseases CardioMetabolism

EU

US

Approved

Pending approval

Status as of April 19, 2016

Japan-Chugai

osteoporosis (oral) Bonviva

January 2016 Alecensa (alectinib) ALK+ NSCLC 2L Filed September 2015 Gazyva iNHL rituximab-ref. February 2016 Avastin cervical cancer Filed September 2015 atezolizumab bladder cancer 2L Filed January 2016 Venclexta (venetoclax) 17pdel CLL rel/ref April 2016 atezolizumab NSCLC 2L+ Filed February 2016 MabThera SC* CLL Filed November 2014 Avastin + Tarceva EGFR mut+ NSCLC Filed July 2015 Gazyva iNHL rituximab-ref. Filed September 2015 *CHMP pos. opinion

(55)

Venclexta (venetoclax) +Rituxan FL rel/ref TNBC

Roche Group Development pipeline

Combinations

55 Phase III

(13 AIs)

atezo+Zelboraf+/-Cotellic melanoma atezo+Avastin+chemo solid tumors

atezo+Tarceva/ Alecensa NSCLC atezolizumab +Cotellic solid tumors atezolizumab +ipi/IFN solid tumors

RG7446 RG7446

RG7446 RG7446 RG7446

CD40 MAb+atezolizumab solid tumors RG7876 atezolizumab+Gazyva lymphoma RG7446 emactuzumab + atezolizumab s.tumors RG7155

atezolizumab+Avastin RCC RG7446 atezo+chemo NSCLC non-sq. 1L RG7446 NSC RG7446 atezo+chemo+Avastin NSCLC non-sq. 1L

atezolizumab+chemo NSCLC sq. 1L RG7446

New Molecular Entity (NME) Additional Indication (AI)

Oncology Immunology

RG-No Roche Genentech managed

OX40 MAb + atezolizumab s. tumors RG7888 atezo+lenalidomide multiple myeloma RG7446

atezolizumab+abraxane TNBC RG7446 CEA IL2v FP+atezolizumab s. tumors RG7813

IDO inh + atezolizumab solid tumors RG6078

Venclexta+Gazyva CLL

ERK inh + Cotellic solid tumors RG7601

RG7842

Cotellic+paclitaxel TNBC RG7421

lebrikizumab +/- Esbriet IPF RG7601

RG3637

RG1273 Perjeta+Herceptin HER2+gastric ca 1L

RG1273 Perjeta+Herceptin HER2+ mBC 2L

RG7601 Venclexta(venetoclax)+RituxanCLL rel/ref Kadcyla + Perjeta HER2+ BC adj RG3502 Kadcyla + Perjeta HER2+ BC neoadj RG3502 Perjeta+Herceptin RG1273 HER2+ BC adj

Venclexta (venetoclax)+Gazyva CLL 1L RG7601

Avastin+Tarceva EGFR mut+ NSCLC RG4351

1 EU only

Phase I

(5 NMEs + 16 AIs)

Phase II

(3 Als)

Registration

(1 AI)

RG7446 atezolizumab + K/ H+P HER2+BC

CEA CD3 TCB+atezolizumab s. tumors RG7802

Status as of April 19, 2016

Erivedge+Esbriet IPF RG3616 RG7159 Gazyva multiple combos heme indications

Erivedge+ruxolitinib myelofibrosis RG3616 RG7601 Venclexta+Cotellic/idasanutlin AML CLL

(56)

Cancer immunotherapy pipeline overview

56 Phase I

(8 NMEs + 19 AIs)

atezo+Avastin+chemo solid tumors

atezo+Tarceva NSCLC EGFR+ atezolizumab +Cotellic solid tumors atezolizumab solid tumors

atezolizumab +ipi/IFN solid tumors

OX40 MAb solid tumors RG7446 RG7446 RG7446 RG7446 RG7446 RG7888

CEA CD3 TCB + atezolizumab s. tumors RG7802

CD40 MAb+atezolizumab solid tumors RG7876 atezolizumab+Gazyva lymphoma RG7446 emactuzumab + atezolizumab s.tumors RG7155

IDO inh solid tumors RG6078 atezolizumab bladder cancer 2L RG7446 1

*INCY atezolizumab + IDO inh solid tumors *CLDX atezolizumab+varlilumab solid tumors

New Molecular Entity (NME) Additional Indication (AI)

Oncology

RG-No Roche Genentech managed

OX40 MAb + atezolizumab solid tumors RG7888 RG7446 atezo+lenalidomide/daratumumab MM

Phase II

(2 AIs)

atezo+NY-ESO-1 soft tissue sarcoma IMDZ NSC atezo+entinostat TNBC SNDX

CEA IL2v FP+atezolizumab solid tumors RG7813 IDO inh + atezolizumab solid tumors RG6078

CD20/CD3 biMAb hem tumors RG7828

Registration

(1 NME + 1 AI)

FAP IL2v FP solid tumors RG7461

Status as of April 19, 2016

atezo+Zelboraf+/-Cotellic m. melanoma RG7446

RG7446 atezolizumab + K/HP HER2+ BC

*external collaborations: INCY- Incyte INCB024360, CLDX - Celldex CD27 MAb; CLVS – Clovis EGFRi, CRVS – Corvus CPI-444, KITE – Kite KTE-C19, AMGN – Amgen oncolytic virus, JNJ – Janssen CD38 MAb., IMDZ – Immune Design CMB305, SNDX – Syndax HDACi

*CLVS atezo+rociletinib EGFRmut+ NSCLC

RG74461 atezolizumab NSCLC 2L

1 Phase 3 ongoing

*CRVS atezo+A2Ai solid tumors *KITE atezo+CD19 CAR-T NHL atezo+talimogene laherp. TNBC, CRC *AMGN *JNJ atezo+daratumumab solid tumor

Phase III

(10 AIs)

atezolizumab+Avastin RCC RG7446 atezo+chemo NSCLC non-sq. 1L RG7446 NSC RG7446 atezo+chemo+Avastin NSCLC non-sq. 1L atezolizumab+chemo NSCLC sq. 1L RG7446 atezolizumab Dx+ NSCLC sq. 1L RG7446 atezolizumab Dx+ NSCLC non-sq. 1L RG7446 atezolizumab+abraxane TNBC RG7446 atezolizumab Dx+ NSCLC adj RG7446

atezolizumab muscle inv. bladder ca adj RG7446

(57)